Advertisement

Topics

Safety and Efficacy of Secukinumab in Mild Psoriasis

2017-04-28 09:23:22 | BioPortfolio

Summary

Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic inflammation that leads to psoriatic arthritis and cardiovascular comorbidities. By curing mild psoriasis with a short-term anti- interleukin (IL)-17A treatment, investigators may reduce the costs of treating psoriasis and associated medical conditions, including psoriatic arthritis, cardiovascular disease, and diabetes.

Description

Psoriasis is an immune-mediated disease of the skin that, even in mild disease, increases the risk of comorbidities such as cardiovascular disease and metabolic derangements. Mild psoriasis tends to be treated with topical drugs, while moderate-to-severe disease is optimally treated with systemic immune modulators. However, the treatment of "mild" psoriasis needs to be re-thought because recent studies have revealed that mild psoriasis is characterized by stronger expression of pathogenic molecules, such as interleukin (IL)-17A, and higher numbers of T cells in the skin, compared to severe psoriasis. A key distinction between mild and severe psoriasis is now discovered to be the higher expression of negative immune regulatory genes in mild lesions. Therefore, targeted immune therapy with anti-IL-17A, which is highly effective in severe psoriasis, might be equally (or even more) effective in mild disease. Also, restoration of immune tolerance might be more easily achieved in mild disease. Thus, short-term anti-IL-17A treatment of mild psoriasis might prevent the recurrence and eventually cure the disease. The aim of study is to test this hypothesis by exploring whether 3 months or 6 months of anti-IL17A treatment will prevent relapses after medication has been discontinued in mild psoriasis patients.

Study Design

Conditions

Psoriasis

Intervention

Secukinumab, Placebo followed by Secukinumab

Location

The Rockefeller Univesity
New York
New York
United States
10065

Status

Not yet recruiting

Source

Rockefeller University

Results (where available)

View Results

Links

Published on BioPortfolio: 2017-04-28T09:23:22-0400

Clinical Trials [695 Associated Clinical Trials listed on BioPortfolio]

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

The purpose of this study is to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis

Study of Secukinumab With 2 mL Pre-filled Syringes

The aim of the study is to demonstrate efficacy, safety and tolerability of 2 mL pre-filled syringe of 300 mg secukinumab in treatment of moderate to severe plaque psoriasis.

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

This is an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukin...

Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab

The purpose of this study is to explore the effect of treatment with 300 mg or with 150 mg secukinumab (administered weekly for 4 weeks followed by four-weekly administration) on endotheli...

Plaque Psoriasis Efficacy and Safety With Secukinumab

To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c. ev...

PubMed Articles [1183 Associated PubMed Articles listed on BioPortfolio]

Scalp psoriasis: report of efficient treatment with secukinumab.

Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population in the world. The scalp is the most common, and frequently the first site of disease involvement. Occasionally it may ...

Secukinumab efficacy in the treatment of nail psoriasis: a case series.

Nail involvement is frequent in patients with psoriasis, especially those with psoriatic arthritis, and can significantly impair quality of life. It is typically difficult to treat compared with skin ...

Secukinumab for moderate to severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.

Palmoplantar pustular psoriasis (PPP) is a debilitating disease of the palms and/or soles that is resistant to treatment. Secukinumab, an anti-IL-17A monoclonal antibody, is highly efficacious in the ...

Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experience.

Ocular comorbidity has been reported in 10-15% of patients with plaque psoriasis. This paper reports successful treatment with secukinumab of a patient with plaque psoriasis and dry eye syndrome. Both...

Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis.

Many pediatric psoriasis patients suffer from nail involvement and psoriatic arthritis. In adults, biologic agents have demonstrated success in treating refractory nail psoriasis and arthritis, but st...

Medical and Biotech [MESH] Definitions

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

More From BioPortfolio on "Safety and Efficacy of Secukinumab in Mild Psoriasis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...


Searches Linking to this Trial